A Phase I/II Trial of the Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat assessing Efficacy and Safety in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma

Trial Profile

A Phase I/II Trial of the Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat assessing Efficacy and Safety in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Panobinostat (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Jan 2016 New trial record
    • 08 Dec 2015 Interim results (n=42) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top